Boom in the development of non-peptidic
β
Romano Silvestri
π
Article
π
2009
π
John Wiley and Sons
π
English
β 623 KB
## Abstract Ξ²βAmyloid cleaving enzymeβ1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first nonβpeptidomimetic Ξ²βsecretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The nonβ